PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 19, 2024Internal Medicine4 citationsOpen Access

Efficacy of Amamorelin in Advanced Pancreatic Cancer Patients with a Poor Performance Status

View Full Paper
TTTsuyoshi TakedaTSTakashi SasakiTOTakeshi Okamoto

Key Points

Key points are not available for this paper at this time.

Abstract

Objective The efficacy of anamorelin in pancreatic cancer (PC) patients with a poor performance status (PS) is uncertain, as previous trials have excluded such patients. This study evaluated the efficacy of anamorelin in PC patients with a poor PS (2) compared with those with a good PS (0-1).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Takeda et al. (2024) studied this question.

synapsesocial.com/papers/68e64198b6db6435875d39aehttps://doi.org/10.2169/internalmedicine.3577-24
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of the Extent of Weight Loss before Administration on the Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with Cachexia2022 · 19 citations
  2. 2Efficacy and safety of anamorelin in patients with cancer cachexia: Post‐hoc subgroup analyses of a placebo‐controlled study2022 · 28 citations
  3. 3A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in patients with cancer cachexia and low body mass index2022 · 46 citations
  4. 4The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy2021 · 53 citations
  5. 5Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics2012 · 19,249 citations